Sound View Wealth Advisors Group LLC Purchases 360 Shares of Humana Inc. $HUM

Sound View Wealth Advisors Group LLC raised its position in shares of Humana Inc. (NYSE:HUM) by 31.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,514 shares of the insurance provider’s stock after acquiring an additional 360 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Humana were worth $370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Humana by 8.9% during the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock valued at $3,697,222,000 after purchasing an additional 1,143,662 shares in the last quarter. Dodge & Cox increased its holdings in shares of Humana by 5.5% in the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock worth $2,845,830,000 after buying an additional 557,175 shares during the last quarter. Pzena Investment Management LLC raised its position in shares of Humana by 6.5% during the 2nd quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock valued at $996,664,000 after buying an additional 247,744 shares in the last quarter. Davis Selected Advisers lifted its holdings in shares of Humana by 3.3% in the 1st quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider’s stock valued at $616,873,000 after acquiring an additional 74,434 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its position in Humana by 1.6% in the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider’s stock worth $327,293,000 after acquiring an additional 19,613 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of NYSE:HUM opened at $238.06 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm’s 50 day simple moving average is $276.72 and its 200-day simple moving average is $258.65. The firm has a market cap of $28.63 billion, a PE ratio of 18.27, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. Humana Inc. has a one year low of $206.87 and a one year high of $315.35.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.29. The business had revenue of $32.65 billion during the quarter, compared to analysts’ expectations of $31.99 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business earned $4.16 EPS. As a group, equities analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, December 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.5%. Humana’s payout ratio is currently 33.18%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HUM. Wells Fargo & Company raised their price objective on Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a research note on Tuesday, October 7th. Bank of America increased their price target on Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a report on Friday, October 10th. Guggenheim reaffirmed a “buy” rating on shares of Humana in a research note on Friday, October 3rd. Wolfe Research boosted their price objective on shares of Humana from $283.00 to $313.00 and gave the company an “outperform” rating in a research report on Monday, October 6th. Finally, Piper Sandler reduced their target price on shares of Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a research note on Thursday, July 31st. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $298.39.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.